Samenvatting van de aanvraag

Dit item is dichtgeklapt
Dit item is opengeklapt

Group B Streptococcal Disease (GBS) is considered the most frequent cause of serious infection among newly born children. Its prevention could help reduce infant mortality, morbidity and related long-term disabilities. Rapid screening tests recently developed in the United States provide a potential alternative to the time-consuming tests currently employed and offer new perspectives in the prevention of GBS-related disease. However, before these tests will arrive on the Dutch market, consideration of their costs and their outcomes is necessary. Further, the manner in which the rapid tests can be implemented in the Dutch obstetric care system is likely to have a large impact on the eventual (cost) effectiveness. Evaluation of the (cost-)effectiveness of the current and alternative potential prevention strategies provides the motivation for this proposal, taking into account these new developments. This evaluation will be performed using decision analytic techniques. To feed the model, data from a variety of sources will be gathered: from literature review, secondary analysis of existing data, interviews with care professionals and interviews with parents of children with GBS-related illness, respectively.

The result of the cost-effectiveness analysis will enable care professionals and policy makers to choose the best and most (cost-)effective strategy to prevent GBS-related disease.

Naar boven
Direct naar: InhoudDirect naar: NavigatieDirect naar: Onderkant website